NSAM
DNA icon

North Star Asset Management’s Ginkgo Bioworks DNA Stock Holding History

North Star Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,778
Closed -$77.3K – 326
2024
Q2 		$77.3K Buy
5,778
+3,578
+163% +$107K ﹤0.01% 305
2024
Q1 		$102K Buy
2,200
+646
+42% +$33.4K ﹤0.01% 308
2023
Q4 		$105K Buy
1,554
+200
+15% +$12.2K 0.01% 302
2023
Q3 		$98K Buy
1,354
+891
+192% +$71.2K 0.01% 289
2023
Q2 		$34.4K Sell
463
-40
-8% -$2.37K ﹤0.01% 297
2023
Q1 		$26.7K Sell
503
-412
-45% -$26.1K ﹤0.01% 301
2022
Q4 		$61.9K Buy
915
+275
+43% +$25.3K ﹤0.01% 303
2022
Q3 		$80K Sell
640
-41
-6% -$4.89K 0.01% 289
2022
Q2 		$65K Buy
+681
New +$83.1K ﹤0.01% 290

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

North Star Asset Management's DNA Position: Q3 2024 in Review

North Star Asset Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 5,778 shares — an estimated $77.3K sold.

North Star Asset Management first reported a position in DNA in Q2 2022 and held it in 9 quarters. The position peaked at $105K in Q4 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • North Star Asset Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • North Star Asset Management sold 5,778 Ginkgo Bioworks shares in Q3 2024, an estimated $77.3K.
  • North Star Asset Management first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 9 quarters.
  • North Star Asset Management's Ginkgo Bioworks position peaked at $105K in Q4 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on North Star Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.